Table 3.
ONPS mean C t with each assay according to the NAATS result obtained for saliva when ONPS was positive (n = 271)
| Method | Saliva | ONPS mean C t | Range | p Valuea | |
|---|---|---|---|---|---|
| result | n | ||||
| Abbott RealTime SARS‐CoV‐2 assay (n = 38) | − | 10 | 24.8 | 21.3–28.3 | 0.01 |
| + | 28 | 17.1 | 14.1–20.2 | ||
| Cobas® SARS‐CoV‐2 test (n = 15) | − | 2 | 33.4 | 31.3–35.4 | NS |
| + | 13 | 28.3 | 24.9–31.7 | ||
| Allplex™ 2019‐nCoV assay (n = 24) | − | 2 | 30.2 | −28.0–88.4 | NS |
| + | 22 | 28.4 | 26.3–30.5 | ||
| Simplexa® COVID‐19 Direct Kit (n = 41) | − | 4 | 31.0 | 27.7–34.2 | 0.03 |
| + | 37 | 24.2 | 22.3–26.1 | ||
| RIDA®GENE SARS‐CoV‐2 test using BD MAX™ Isolation Kit (n = 32) | − | 1 | 35.5 | NA | NS |
| + | 31 | 26.7 | 24.4–29.0 | ||
| LDT/Cobas 4800 system (n = 20) | − | 0 | NA | NA | NA |
| + | 20 | 30.0 | 28.3–31.8 | ||
| LDT/NucliSens easyMAG platform (n = 51) | − | 17 | 32.7 | 31.6–33.7 | <0.001 |
| + | 34 | 25.7 | 23.8–27.6 | ||
| LDT/thermal lysis (n = 50) | − | 7 | 34.1 | 30.0–38.2 | 0.01 |
| + | 43 | 29.5 | 28.0–31.0 | ||
Abbreviations: C t, cycle threshold; 95% CI, 95% confidence interval; LDT, laboratory‐developed tests; ONPS, oral and nasopharyngeal swab; NA, not applicable; NAAT, nucleic acid amplification test; NS, not significant; n, number of samples; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2; +, detected; −, not detected.
a
Two‐sample Wilcoxon rank‐sum (Mann–Whitney) test.